Edward Carr, CHIEF ACCOUNTING OFFICER at Dianthus Therapeutics, Inc. /DE/ (DNTH), sold 20,000 shares at $100.43 ($2.0M) on 2026-09-17, disclosed to the SEC on 2026-09-18.
Scheduled sale ($2.0M) by CHIEF ACCOUNTING OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $100.43 | 7,928 | $796K | 39.3% |
| 2 | $101.37 | 6,771 | $686K | 33.9% |
| 3 | $102.39 | 3,501 | $358K | 17.7% |
| 4 | $103.20 | 1,100 | $114K | 5.6% |
| 5 | $104.39 | 700 | $73K | 3.6% |
| Total | $101.38 avg | 20,000 |
| $2.0M |
| 100% |
| Filing → |
| ABEO | SELL | 2021-04-05 | $101K | — | Filing → |
| ABEO | SELL | 2020-03-20 | $12K | — | Filing → |